|
SCIENCE NEWS
Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration
According to a recent study, retinal pigmented epithelium stem cells injected into the suprachoroidal space prevented the animal's RPE cell's degeneration and also showed that the fellow contra lateral eye showed a beneficial effect. (Stemedica Cell Technologies, Inc., San Diego)
New Test Can Detect both Genetic and Chromosomal Abnormalities in Embryos
One-step screening for both genetic and chromosomal abnormalities has come closer as scientists announced that an embryo test they have been developing has successfully screened cells taken from spare embryos that were known to have cystic fibrosis. (Genetics & IVF Institute, Fairfax)
Geron Scientists and Collaborators Publish Data Showing Functional Dendritic Cells Can Be Derived From HESCs Using Scalable Production Methods
Geron Corporation recently announced the publication of data demonstrating that dendritic cells scalably manufactured from human embryonic stem cells exhibit the normal functions of naturally occurring human DCs found in the bloodstream. (Geron, Menlo Park)
Bioethicists Call For Public Debates on Future Uses of Stem Cells
More than 40 scientists, bioethicists, lawyers and science journal editors are calling on their colleagues, policy makers and the public to begin developing guidelines for the research and reproductive use of stem cell-derived eggs and sperm, even though such use may be a decade or more away.
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
|
|
INDUSTRY
Connexon Creative Launches Cord Blood News
Cord Blood News is a weekly e-newsletter that keeps members of the cord blood community informed by providing the latest news from all areas of the field, including its science, research, policy, and business.
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
GE Healthcare and Geron Corporation recently announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
iZumi Bio, Inc. and Pierian, Inc. recently announced they have merged to form a new company, iPierian, Inc. Building on the iZumi infrastructure and vision, the company is focused on the application of cellular reprogramming to change the paradigm of drug discovery.
Fate Therapeutics Licenses Stem-Cell Modulators for Bone Regeneration from UCLA
Fate Therapeutics said recently that it has acquired from the University of California, Los Angeles, exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation.
Pluristem Therapeutics Was Awarded a $1.9 Million Grant from the Office of the Chief Scientist in the Israeli Government
Pluristem Therapeutics Inc. announced recently that the company was awarded a $1.9 million government grant from the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of Israel.
First cGMP Feeder-independent Pluripotent Stem Cell Banks Released for Distribution
The WiCell Research Institute and the Waisman Clinical Biomanufacturing Facility announced recently the release of the first current Good Manufacturing Practices feeder-independent pluripotent stem cell banks available for sale and distribution to researchers worldwide.
Start-Ups Say Innovation Doesn't Grow on Trees
When nearly $10 billion in stimulus funds went to the NIH this year, a last-minute change in the legislation exempted the agency from setting aside 2.8 percent of its research budget for small businesses and the commercialization of technologies developed at universities.
|
|
|
This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada |
|
|
